MARKET

MESO

MESO

Mesoblast
NASDAQ
10.89
-0.29
-2.59%
After Hours: 10.89 0 0.00% 19:30 11/20 EST
OPEN
11.19
PREV CLOSE
11.18
HIGH
11.44
LOW
10.87
VOLUME
192.71K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
10.87
MARKET CAP
1.42B
P/E (TTM)
-24.5215
1D
5D
1M
3M
1Y
5Y
1D
Mesoblast reports FY results
Seeking Alpha · 3d ago
Mesoblast Reports US$115M in FY2026 Net Revenue and Outlines Clinical Milestones at ASX Investor Day
NASDAQ · 3d ago
Mesoblast Showcased at ASX Investor Day
TipRanks · 3d ago
Mesoblast Limited Announces Appointment of Jon Voigtman as Director on 10 November 2026
NASDAQ · 4d ago
Weekly Report: what happened at MESO last week (1109-1113)?
Weekly Report · 4d ago
Mesoblast Limited Announces Leadership Changes and Reports US$115M in FY2026 Net Revenue
NASDAQ · 11/12 22:40
Weekly Report: what happened at MESO last week (1102-1106)?
Weekly Report · 11/09 10:18
Mesoblast Reports Director Departure and ASX Filings
TipRanks · 11/03 11:32
More
About MESO
Mesoblast Limited is an Australia-based biotechnology company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company's Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: Chronic heart failure (CHF) and Chronic low back pain (CLBP) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.